Discovery of dibenzo[c,f][2,7]naphthyridines as potent and selective 3-phosphoinositide-dependent kinase-1 inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 23, 2007, Pages 5547-5549

  Gopalsamy, Ariamala ^a   Shi, Mengxiao ^a   Boschelli, Diane H ^a   Williamson, Robert ^a   Olland, Andrea ^b   Hu, Yongbo ^a   Krishnamurthy, Girija ^a   Han, Xin ^a   Arndt, Kim ^a   Guo, Bing ^a  

^a WYETH RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHOSPHOINOSITIDE DEPENDENT KINASE 1 INHIBITOR; DIBENZO[C,F][2,7]NAPHTHYRIDINE; GLYCOGEN SYNTHASE KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B BETA; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; S6 KINASE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL GROWTH; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; TUMOR CELL; TUMOR GROWTH;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHYRIDINES; PROTEIN-SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36149000161     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070851i     Document Type: Article

References (18)

1. Mora, A.; Komander, D.; Van Aalten, D. M. F.; Alessi, D. R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 2004, 15, 161-170.
2. Brazil, D. P.; Hemmings, B. A. Ten years of protein kinase B signaling: a hard Akt to follow. Trends Biochem. Sci. 2001, 26, 657-664.
3. Avruch, J.; Belham, C.; Weng, Q.; Hara, K.; Yonezawa, K. The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. Prog. Mol. Subcell. Biol. 2001, 26, 115-154.
4. Lang, F.; Cohen, P. Regulation and physiological roles of serum-and glucocorticoid-induced protein kinase isoforms. Sci. STKE 2001, 108, RE17.
5. Newton, A. C. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem. J. 2003, 370, 361-371.
6. Cully, M.; You, H.; Levine, A. J.; Mak, T. W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6, 184-192.
7. Binch, H.; Mortimore, M.; Robinson, D.; Stamos, D. Preparation of azinylbenzimidazolamines as Aurora, FLT-3, or PDK1 protein kinase inhibitors. WO 2007015923, 2007.
8. Walmsley, D. L.; Drysdale, M. J.; Northfield, C. J.; Fromont, C. Preparation of pyrazolylbenzimidazoles as PDK1 and CHK1 kinase inhibitors for the treatment of cancer and autoimmune disorders. WO 2006134318, 2006.
9. Tseng, P.; Wang, Y.; Weng, S.; Weng, J.; Chen, C.; Brueggemeier, R. W.; Shapiro, C. L.; Chen, C. D.; Dunn, S. E.; Pollak, M.; Chen, C. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol. Pharmacol. 2006, 70, 1534-1541.
10. Daly, K.; Heron, N.; Hird, A.; Ioannidis, S.; Janetka, J. W.; Lyne, P.; Scott, J.; Toader, D.; Vasbinder, M.; Yu, D.; Yu, Y. Substituted thienopyridines and related compounds and their preparation, pharmaceutical compositions, and use as CHK1, PDK1 and PAK inhibitors in the treatment of cancer. WO 2006106326, 2006.
11. (a) Islam, I.; Bryant, J.; Chou, Y.; Kochanny, M. J.; Lee, W.; Phillips, G. B.; Yu, H.; Adler, M.; Whitlow, M.; Ho, E.; Lentz, D.; Polokoff, M. A.; Subramanyam, B.; Wu, J. M.; Zhu, D.; Feldman, R. I.; Arnaiz, D. O. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity. Bioorg. Med. Chem. Lett. 2007, 17, 3814-3818.
12. (b) Islam, I.; Brown, G.; Bryant, J.; Hrvatin, P.; Kochanny, M. J.; Phillips, G. B.; Yuan, S.; Adler, M.; Whitlow, M.; Lentz, D.; Polokoff, M. A.; Wu, J. M.; Shen, J.; Walters, J.; Ho, E.; Subramanyam, B.; Zhu, D.; Feldman, R. I.; Arnaiz, D. O. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517. Bioorg. Med. Chem. Lett. 2007, 17, 3819-3825.
13. Capraro, H.; Furet. P.; Garcia-Echeverria, C.; Stauffer, F. Preparation of 1H-imidazo[4,5-c]quinolines for the treatment of protein kinase dependent diseases. WO 2005054238, 2005.
14. Wissner, A.; Berger, D. M.; Boschelli, D. H.; Floyd, M. B.; Greenberger, L. M.; Gruber, B. C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H.; Upeslacis, E.; Wang, Y.; Wu, B.; Ye, F.; Zhang, N. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J. Med. Chem. 2000, 43, 3244-3256.
15. Gopalsamy, A.; Shi, M.; Nilakantan, R. An efficient synthesis of dibenzo[c,f]-2,7-naphthyridine ring system through design of experiments. Org. Process Res. Dev. 2007, 11, 450-454.
16. Boschelli, D. H.; Wang, Y. D.; Johnson, S.; Wu, B.; Ye, F.; Sosa, A.; Golas, J. M.; Boschelli, F. 7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases. J. Med. Chem. 2004, 47, 1599-1601.
17. Unless indicated, data are reported as the average of two or more experiments (each run in duplicate).
18. PDB code: 2R7B.